D.E. Shaw & Co
ANIP icon

D.E. Shaw & Co’s ANI Pharmaceuticals ANIP Stock Holding History

D.E. Shaw & Co’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,700
Closed -$228K – 3901
2019
Q4 		$228K Hold
3,700
– – ﹤0.01% 3749
2019
Q3 		$270K Buy
+3,700
New +$277K ﹤0.01% 3509
2017
Q1 		– Sell
-40,000
Closed -$2.42M – 3270
2016
Q4 		$2.42M Hold
40,000
– – ﹤0.01% 1850
2016
Q3 		$2.65M Buy
40,000
+10,000
+33% +$625K ﹤0.01% 1710
2016
Q2 		$1.68M Buy
+30,000
New +$1.46M ﹤0.01% 2056
2015
Q2 		– Sell
-20,000
Closed -$1.25M – 3729
2015
Q1 		$1.25M Buy
+20,000
New +$1.22M ﹤0.01% 2380

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's ANIP Position: Q1 2026 in Review

D.E. Shaw & Co reduced its ANI Pharmaceuticals (ANIP) stake by 16% in Q1 2026, selling an estimated $3.13M and leaving 213,433 shares worth $16.4M. The position accounts for 0.01% of the portfolio, ranked #1276.

D.E. Shaw & Co first reported a position in ANIP in Q2 2013 and has held it in 27 quarters since. The position peaked at $20M in Q4 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • D.E. Shaw & Co held 213,433 shares of ANI Pharmaceuticals worth $16.4M as of Q1 2026.
  • D.E. Shaw & Co sold 40,103 ANI Pharmaceuticals shares in Q1 2026, an estimated $3.13M.
  • ANI Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1276 holding.
  • D.E. Shaw & Co first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • D.E. Shaw & Co's ANI Pharmaceuticals position peaked at $20M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.